Thiazolidinediones

Clifford J. Bailey

doi:10.1016/B978-008055232-3.61047-5

Thiazolidinediones

Clifford J. Bailey^*

^*Corresponding author for this work

Research output: Chapter in Book/Published conference output › Chapter (peer-reviewed) › peer-review

3 Citations (Scopus)

Abstract

Thiazolidinediones (TZDs), also termed "glitazones", are used as antidiabetic agents for the treatment of type 2 (non-insulin dependent) diabetes mellitus. They activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). This increases the transcription of various insulin-sensitive genes, improving insulin action and lowering blood glucose concentrations. TZDs currently in clinical use for the treatment of type 2 diabetes are rosiglitazone and pioglitazone. Troglitazone was withdrawn due to hepatotoxicity. Other TZDs (e.g. ciglitazone) have been studied preclinically, but not introduced into clinical use. TZDs do not cause severe hypoglycemia, hence they are regarded as antihyperglycemic (rather than hypoglycemic) agents ....

Original language	English
Title of host publication	xPharm
Subtitle of host publication	the comprehensive pharmacology reference
Editors	S.J. Enna, David B. Bylund
Publisher	Elsevier
Number of pages	2
ISBN (Print)	978-0-08-055232-3
DOIs	https://doi.org/10.1016/B978-008055232-3.61047-5
Publication status	Published - Feb 2011

Bibliographical note

Updated by C.J. Bailey, Thiazolidinediones, Reference Module in Biomedical Sciences, 2015.

Access to Document

10.1016/B978-008055232-3.61047-5

Cite this

@inbook{e13b26c7a3274b0e9e0d9f3b582f960f,

title = "Thiazolidinediones",

abstract = "Thiazolidinediones (TZDs), also termed {"}glitazones{"}, are used as antidiabetic agents for the treatment of type 2 (non-insulin dependent) diabetes mellitus. They activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). This increases the transcription of various insulin-sensitive genes, improving insulin action and lowering blood glucose concentrations. TZDs currently in clinical use for the treatment of type 2 diabetes are rosiglitazone and pioglitazone. Troglitazone was withdrawn due to hepatotoxicity. Other TZDs (e.g. ciglitazone) have been studied preclinically, but not introduced into clinical use. TZDs do not cause severe hypoglycemia, hence they are regarded as antihyperglycemic (rather than hypoglycemic) agents ....",

author = "Bailey, \{Clifford J.\}",

note = "Updated by C.J. Bailey, Thiazolidinediones, Reference Module in Biomedical Sciences, 2015. ",

year = "2011",

month = feb,

doi = "10.1016/B978-008055232-3.61047-5",

language = "English",

isbn = "978-0-08-055232-3",

editor = "S.J. Enna and Bylund, \{David B.\}",

booktitle = "xPharm",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Thiazolidinediones

AU - Bailey, Clifford J.

N1 - Updated by C.J. Bailey, Thiazolidinediones, Reference Module in Biomedical Sciences, 2015.

PY - 2011/2

Y1 - 2011/2

N2 - Thiazolidinediones (TZDs), also termed "glitazones", are used as antidiabetic agents for the treatment of type 2 (non-insulin dependent) diabetes mellitus. They activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). This increases the transcription of various insulin-sensitive genes, improving insulin action and lowering blood glucose concentrations. TZDs currently in clinical use for the treatment of type 2 diabetes are rosiglitazone and pioglitazone. Troglitazone was withdrawn due to hepatotoxicity. Other TZDs (e.g. ciglitazone) have been studied preclinically, but not introduced into clinical use. TZDs do not cause severe hypoglycemia, hence they are regarded as antihyperglycemic (rather than hypoglycemic) agents ....

AB - Thiazolidinediones (TZDs), also termed "glitazones", are used as antidiabetic agents for the treatment of type 2 (non-insulin dependent) diabetes mellitus. They activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). This increases the transcription of various insulin-sensitive genes, improving insulin action and lowering blood glucose concentrations. TZDs currently in clinical use for the treatment of type 2 diabetes are rosiglitazone and pioglitazone. Troglitazone was withdrawn due to hepatotoxicity. Other TZDs (e.g. ciglitazone) have been studied preclinically, but not introduced into clinical use. TZDs do not cause severe hypoglycemia, hence they are regarded as antihyperglycemic (rather than hypoglycemic) agents ....

UR - https://www.scopus.com/pages/publications/84884013863

U2 - 10.1016/B978-008055232-3.61047-5

DO - 10.1016/B978-008055232-3.61047-5

M3 - Chapter (peer-reviewed)

SN - 978-0-08-055232-3

BT - xPharm

A2 - Enna, S.J.

A2 - Bylund, David B.

PB - Elsevier

ER -

Thiazolidinediones

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Biguanides

Ciglitazone

Metformin

Cite this